Fixed Duration Ibrutinib‐Venetoclax, a Redefinition of the CLL Treatment Landscape
(2025)
Journal Article
Molica, S., & Allsup, D. (2025). Fixed Duration Ibrutinib‐Venetoclax, a Redefinition of the CLL Treatment Landscape. Hematological Oncology, 43(3), Article e70088. https://doi.org/10.1002/hon.70088
The fixed-duration combination of ibrutinib and venetoclax (IV) has emerged as a highly effective therapeutic strategy for treating chronic lymphocytic leukemia (CLL), marking a significant shift in the treatment paradigm for this disease. Preclinica... Read More about Fixed Duration Ibrutinib‐Venetoclax, a Redefinition of the CLL Treatment Landscape.